Immunogenetherapy of Cancer Using Recombinant Adenovirus Expressing Type III interferon IL-28A or IL-29

Muneo Numasaki^1*, Masatoshi Tagawa², Hiroki Tsukamoto³, Yoshihisa Tomioka³, Takashi Ohrui⁴ and Hiroyuki Arai¹

¹Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Miyagi, Japan

²Division of Pathology and Cell Therapy, Chiba Cancer Centre Research Institute, Chiba, Japan

³Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan

⁴Division of Geriatric Pharmacotherapy, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

^*Corresponding Author: Muneo Numasaki, Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Miyagi, Japan, Tel: +81-22-717-7182 Email:

Short Communication